PT  - JOURNAL ARTICLE
AU  - Caroff, Jildaz
AU  - Aubert, Laurent
AU  - Lavenu-Bombled, Cécile
AU  - Figueiredo, Samy
AU  - Habchi, Kamelia
AU  - Cortese, Jonathan
AU  - Eugene, Francois
AU  - Ognard, Julien
AU  - Tahon, Florence
AU  - Forestier, Géraud
AU  - Ifergan, Heloise
AU  - Zhu, François
AU  - Hak, Jean-Francois
AU  - Reyre, Anthony
AU  - Laubacher, Morgane
AU  - Traore, Abdoulaye
AU  - Desilles, Jean Philippe
AU  - Derraz, Imad
AU  - Moreno, Ricardo
AU  - Bintner, Marc
AU  - Charbonnier, Guillaume
AU  - Le Bras, Anthony
AU  - Veunac, Louis
AU  - Gariel, Florent
AU  - Redjem, Hocine
AU  - Sedat, Jacques
AU  - Tessier, Guillaume
AU  - Dumas, Victor
AU  - Gauberti, Maxime
AU  - Chivot, Cyril
AU  - Consoli, Arturo
AU  - Bricout, Nicolas
AU  - Tuilier, Titien
AU  - Guedon, Alexis
AU  - Pop, Raoul
AU  - Thouant, Pierre
AU  - Bellanger, Guillaume
AU  - Zannoni, Riccardo
AU  - Soize, Sebastien
AU  - Richter, Johann Sebastian
AU  - Heck, Olivier
AU  - Mihalea, Cristian
AU  - Burel, Julien
AU  - Girot, Jean-Baptiste
AU  - Shotar, Eimad
AU  - Gazzola, Sebastian
AU  - Boulouis, Gregoire
AU  - Kerleroux, Basile
ED - 
TI  - Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey
AID  - 10.1136/neurintsurg-2021-018601
DP  - 2023 Apr 01
TA  - Journal of NeuroInterventional Surgery
PG  - 402--407
VI  - 15
IP  - 4
4099  - http://jnis.bmj.com/content/15/4/402.short
4100  - http://jnis.bmj.com/content/15/4/402.full
SO  - J NeuroIntervent Surg2023 Apr 01; 15
AB  - Background Neurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity in antithrombotic use between centers. Through a nationwide survey, we aimed to obtain an exhaustive cross-sectional overview of antithrombotic use in neurointerventional procedures in France.Methods In April 2021, French neurointerventional surgery centers were invited to participate in a nationwide 51-question survey disseminated through an active trainee-led research collaborative network (the JENI-RC).Results All 40 centers answered the survey. Fifty-one percent of centers reported using ticagrelor and 43% used clopidogrel as premedication before intracranial stenting. For flow diversion treatment, dual antiplatelet therapy was maintained for 3 or 6 months in 39% and 53% of centers, respectively, and aspirin was prescribed for 12 months or more than 12 months in 63% and 26% of centers, respectively. For unruptured aneurysms, the most common heparin bolus dose was 50 IU/kg (59%), and only 35% of centers monitored heparin activity for dose adjustment. Tirofiban was used in 64% of centers to treat thromboembolic complications. Fifteen percent of these comprehensive stroke centers reported using tenecteplase to treat acute ischemic strokes. Cangrelor appeared as an emergent drug in specific indications.Conclusion This nationwide survey highlights the important heterogeneity in clinical practices across centers. There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field.Data are available upon reasonable request.